The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Abstract
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients progressing on first-line regimens can be offered the possibility of switching to the other regimen, or a second-line regimen that includes a liposomal formulation of irinotecan in combination with 5-FU10, provided they have not received either of these agents previously.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [10]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Self-citationKalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J. E., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Self-citationPharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
Self-citationKo, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Self-citationRoy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont?
Wenning, A. S., Ryser, C. O., Andreou, A., Gloor, B., & Berger, M. D. (2021) · Schweizer Gastroenterologie · doi:10.1007/s43472-021-00054-y · Cited by 1
Tian, W., Zhang, L., Liu, X., Ma, X., & Wang, R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282360 · Cited by 1
“We found that Wang 2015 had 117 and 149 patients in the 2 arms, which indicated some imbalance in the randomization [9].”
BackgroundResultPancreatic adenocarcinoma — current trends in diagnosis and treatment
Gruszczyńska, A., Kowalik, K., Hetman, K., & Modrzejewski, A. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0016 · Cited by 1
Lin, C., Cheng, W.-T., Chen, T., Chen, T.-L., Sheu, M., & Lin, H.-L. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123370 · Cited by 1
Li, X., Xiao, C., Li, R., Zhang, P., Yang, H., & Cao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326556 · Cited by 1
Carconi, C., Bosi, C., Scartozzi, M., Cergnul, M., Cinausero, M., Faloppi, L., Garajová, I., Lonardi, S., Pecora, I., Pisanu, L., et al. (2024) · Pancreatology · doi:10.1016/j.pan.2024.09.006 · Cited by 1
Nano-enabled pharmacogenomics: revolutionizing personalized drug therapy
Tıwarı, R., Dev, D., Thalla, M., Aher, V. D., Mundada, A. B., Mundada, P. A., & Vaghela, K. (2024) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2024.2431426 · Cited by 11
“Onivyde gave a better survival than the normal Iriinotecan when tested on patients with pancreatic cancer that had advanced to third phase, especially when used together with 5-fluorouracil and leucovo-rin [64].”
Lan, C.-C., Chiu, T., Hung, C., Yeh, K., Lu, C., Chen, Y., Chen, J., Hung, Y., & Chou, W. (2025) · Pancreatology · doi:10.1016/j.pan.2025.01.012 · Cited by 1
Self-citationVigié, T., Perrier, A., Chanez, B., de Martino, J., Favre, L., Coulet, F., Bachet, J., Guillerm, E., & Mas, L. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312078 · Cited by 1
Okada, Y., Sato, Y., Shinomiya, R., Miyake, T., Takahashi, T., Yokoyama, R., Mitsui, Y., Tomonari, T., Okamoto, K., Sogabe, M., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02677-y · Cited by 1
“The PFS and OS of nal-IRI + 5FU/LV were reported to be 3.1 months and 6.1 months, respectively, in the NAPOLI-1 phase 3 study [24, 33].”
InfluentialARHGAP11A is a potential prognostic biomarker and therapeutic target for pancreatic adenocarcinoma
Shu, Q.-A., Huang, X., Wu, J., Liang, X.-R., Wang, Y., Yu, J., Wang, Z., Liu, N., Wang, J., & Xie, N. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106804 · Cited by 2
In vitro release method development for Onivyde® using Agilent NanoDis® system
Li, J., Juang, V., Lu, Z., Wang, Y., & Schwendeman, A. A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125903 · Cited by 1
Tougeron, D., Mineur, L., Zaanan, A., Kadi, M., Ligeza‐Poisson, C., Bourgeois, V., Martin-Babau, J., Fadin, A., Tallec, V. J.-L., Lebrun, V. L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115741 · Cited by 1
Chun, J. W., Kim, Y. A., Lee, J. W., Lee, D., Jang, D. K., Lee, Y. S., Lee, J.-C., Lee, W. J., Hwang, J., & Woo, S. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251370492 · Cited by 1
“2,5,19 We also used PSM to strengthen the validity of our findings by mitigating confounding factors inherent in real-world data.”
InfluentialTang, H. J., Li, Z., You, T., Ying, J., Yuan, M., Cheng, Y., Wang, Y., Wu, H., & Bai, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378698 · Cited by 1
“36 However, nal-IRI/FL was not included in this study due to insufficient sample size, and this therapy has not been widely used in China.”
Yee, N. S., Berg, A. S., Benson, A. B., Turk, A. A., Boland, P. M., & Peterson, C. M. (2025) · JCO oncology advances. · doi:10.1200/oa-25-00047 · Cited by 1
Nishikawa, K., Otsuka, T., Shimokawa, M., Inagaki, T., Komori, A., Todaka, A., Otsu, S., Shibuki, T., Nakazawa, J., Arima, S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14992-2 · Cited by 1
Yang, M., Wu, S., Ho, I., Chiang, N., Hsaio, C., Lin, C., Lien, M., Chang, P. M., Chen, J.-H., Hsieh, C.-Y., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71307 · Cited by 1
Self-citationTrovato, G., Rossini, D., Guidolin, A., Su, Y., Shan, Y., Chiang, N., Chou, W., Bai, L., Bagalá, C., Bensi, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105874 · Cited by 1
“13 Similarly, the CONKO-003 trial demonstrated that the combination of oxaliplatin, fluorouracil, and leucovorin (OFF regimen) improved OS compared with fluorouracil and leu-covorin alone.”
Self-citationNanovesicular Drug Delivery Systems for Overcoming Antibiotic Resistance
Pillai, G., & Jankie, S. (2025) · Cureus · doi:10.7759/cureus.98926 · Cited by 1
“Toxicities were manageable, supporting this regimen as a new treatment option [105].”
Current oncological management options for hepato-pancreato-biliary cancers
Alexander, S., & Menon, S. (2025) · Gastrointestinal Nursing · doi:10.12968/gasn.2024.0116r1 · Cited by 1
Kanno, R., Saito, Y., Takekuma, Y., Harada, K., Komatsu, Y., & Sugawara, M. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00514-6 · Cited by 1
Ripolli, A., Niccolò, N., Kauffmann, E. F., Ginesini, M., Viti, V., Lombardo, C., Vasile, E., Carla, C., Amorese, G., & Boggi, U. (2026) · Updates in Surgery · doi:10.1007/s13304-025-02502-9 · Cited by 1
“A further milestone was liposomal irinotecan (nal-IRI), evaluated in the NAPOLI-1 trial (2015) [ 30].”
Auckley, E. D., Yohay, S., Ying, G. W., Szabó, A., Wittmann, J., Grahl, J., Aldakkak, M., Thalji, S., McFall, T. B., Kurzrock, R., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag040 · Cited by 1
Gehrels, A. M., Pijnappel, E. N., Daalen, E. H. V., Casalino, S., Zecchetto, C., Quinzii, A., Prager, G. W., de Vos‐Geelen, J., Macarulla, T. M., Melisi, D., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116683 · Cited by 1
Self-citationNarayanan, G., Ruiz, E. M., Scagnelli, T., & van der Lei, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-03935-4_22 · Cited by 1
Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets
Murthy, D., Seyhan, A. A., den Hollander, P., Lu, S., Kuburich, N. A., Gould, C., Karam, A., Sun, K., Schupp, P. G., Safran, H., et al. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101476 · Cited by 2
The cutting-edge advancements in biomaterials under the guidance of intelligence and bionics
Teng, Y., Yang, J., Li, T., Yin, Z., An, Q., Shi, Z., Jia, D., Lv, Q., Ramakrishna, S., & Shi, J. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag110 · Cited by 1
“This has demonstrated that in highly aggressive cancers with limited treatment options, nanomedicines can provide clear survival benefits [279, 280].”
Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy
Yang, M., Huang, Y., Qian, W., Zhu, J., Fei, L., Jiao, Z., Wang, J., Wang, Y., Zhu, W., Chen, S., et al. (2026) · Discover Nano · doi:10.1186/s11671-026-04736-x · Cited by 1
Zeng, C., Ahmed, M., Chen, Y.-J., Zhai, S., Olisakwe, S. C., Dykes, P. C., Roberts, T. J., Ufere, N. N., Davis, E., Zhou, L., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11000-6 · Cited by 1
Self-citationWang, Y., Zhang, Y., Wang, X., Zhao, W., Li, Q., Zhou, M., Liu, Y., Yi, X., He, J. I., Li, Y. P., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02712-8 · Cited by 1
Nakaoka, K., Nishijima, A., Asai, Y., Koumura, G., Isomura, M., Uchida, Y., Tanaka, H., Nakano, T., Ueno, S., Kuzuya, T., et al. (2026) · International Cancer Conference Journal · doi:10.1007/s13691-026-00884-0 · Cited by 1
“…nal-IRI + 5-FU/LV is typically positioned after gemcitabine-based therapy in metastatic settings based on findings from the NAPOLI-1 trial [ 5, 12], the present case suggests that, when the disease is localized and a durable response is achieved, later-line therapy can still serve as an…”
Nagata, K., Yasuda, I., Ueda, Y., Kawanaka, H., Sakamoto, J., Ogino, B., Entani, T., Motoo, I., Hayashi, N., Ando, T., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101409 · Cited by 1
Liu, Y., Zhong, R., Yao, F., Wu, X., Zhang, J., & Kou, Z. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103018 · Cited by 1
Shi, S., Wei, M., Du, N., Li, J., Han, B., Wang, W., Hu, X., Luo, F., Xu, J., & Yu, X. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.08.012 · Cited by 1
Li, Q., Hoffman, M. T., Chun, J.-H., Parent, B. D., Hambitzer, F., Peprah, F., Kureshi, C. T. S., Lim, B. S., Chang, E., Walsh, M. J., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.045 · Cited by 1
NAPOLI-1: winning scoop for metastatic pancreatic cancer
Hutchinson, L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.220 · Cited by 1
Bupathi, M., Ahn, D. H., Wu, C. S.-Y., Ciombor, K. K., Stephens, J. A., Reardon, J., Goldstein, D. A., & Bekaii‐Saab, T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0753-9 · Cited by 1
“However, for patients who have failed first-line regimens, there were no standardized second-line therapies until the approval of MM-398 (nanoliposomal irinotecan) in combination with 5-FU [10].”
Self-citationChemotherapy in the Management of Pancreatic Cancer
Chiang, N., & Chen, L. (2017) · Springer eBooks · doi:10.1007/978-3-662-47181-4_37 · Cited by 1
Self-citationVočka, M., & Petruzelka, L. B. (2017) · Klinicka onkologie · doi:10.14735/amko2017452 · Cited by 1
Sequence therapy in metastatic pancreatic cancer
Waidmann, O., Pelzer, U., Boeck, S. H., & Waldschmidt, D. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0581-5640 · Cited by 1
“Therefore, nal-IRI, 5-FU, and folinic acid is the only third-line chemotherapy regimen based on evidence from a phase III trial after gemcitabine-based therapy [19].”
BackgroundInfluentialSelf-citationPancreatic Cancer and Possible Therapeutic Options
Rashid, M. U., Hussain, I., Jehanzeb, S., Ullah, W., Ali, S., Jain, A. G., Kumar, R., Khetpal, N., & Ahmad, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817661-0.00005-6 · Cited by 1
Systemtherapie des metastasierten Pankreaskarzinoms: Aktuelle Standards und Perspektiven
Sinn, M., & Heinemann, V. (2019) · Der Onkologe · doi:10.1007/s00761-019-0569-2 · Cited by 1
Casado, D. I., Tocino, R. V., Fonseca, E., Cigarral, B., Barrios, B., Escalera, E., Claros, J., Figuero, L., Olivares, A., Lopez, A. A., et al. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.01.004 · Cited by 1
Diagnostik und Therapie des Pankreaskarzinoms
Wenzel, P., & von Figura, G. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1221-7306 · Cited by 1
“[20] Wang-Gillam A, Li CP, Bodoky G et al.”
BackgroundSakaguchi, H., Tanimoto, A., Sato, S., Yanagimura, N., Suzuki, C., Takumi, Y., Nishiyama, A., Yamashita, K., Takeuchi, S., Ohtsubo, K., et al. (2021) · Medicine International · doi:10.3892/mi.2021.8 · Cited by 1
71/m in reduziertem Allgemeinzustand mit Sklerenikterus
Schönrock, M., & Sinn, M. (2021) · Der Onkologe · doi:10.1007/s00761-021-01022-6 · Cited by 1
Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects
Yang, Y., Lee, A. C.-L., Lin, L., Chen, Y., Huang, P., Ma, H., Chen, Y., Lo, W., Lan, Y., Fang, W., et al. (2022) · Cancers · doi:10.3390/cancers14030505 · Cited by 1
Self-citationTargeting Anaplastic Lymphoma Kinase in GI Primary Malignancies
Loh, J., Ang, Y. L. E., Jain, A., Yeong, J. P.-S., & Sundar, R. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00208 · Cited by 1
Nanomedicine Applications in Cancer Treatment
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Lozza, I., & Torres‐Suárez, A. I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_294-1 · Cited by 1
Clinical practice guidelines for interventional treatment of pancreatic cancer
Pourali, G., Donyadideh, G., Mehrabadi, S., Fiuji, H., Hassanian, S. M., Ferns, G. A., Khazaei, M., & Avan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19142-8.00008-5 · Cited by 1
A Guanosine-Derived Antitumor Supramolecular Prodrug
Wang, S., Hu, N., Deng, B., Wang, H., Qiao, R., & Li, C. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00990 · Cited by 1
Self-citationWu, D., Wang, Q., Yan, S., Sun, X., Qin, Y., Yuan, M., Wang, N.-Y., & Huang, X. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i7.1296 · Cited by 1
Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin
Ito, T., Suno, M., Egawa, H., Hiraoka, S., Kamei, K., Sano, S., Ashida, R., Kawai, M., & Matsubara, K. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10315 · Cited by 1
Lipid nanoparticles loaded with anticancer bioactives: state of the art
Faria, G. N. F., Bhavsar, D., Munshi, A., & Ramesh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15401-0.00017-8 · Cited by 1
Okuno, M., Mukai, T., Iwata, K., Takagi, A., Ito, Y., Ohashi, Y., Tezuka, R., Iwasa, Y., Iwata, S., & Tomita, E. (2024) · Medical Oncology · doi:10.1007/s12032-024-02438-x · Cited by 1
“Although direct comparison of AEs between second-line nal-IRI and S-IROX therapies is challenging, toxicity, particularly diarrhea and neutropenia, appeared higher with S-IROX than with nal-IRI therapy [11, 14, 18].”
UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan–Related Toxicity
Liang, Y., & Ando, Y. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01366 · Cited by 1
Kim, H. S., Chae, H., Lim, S. Y., Jeong, H. J., Yoon, S. J., Shin, S. H., Han, I. W., Heo, J. S., & Kim, H. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16792-7 · Cited by 1
“…patients with stage III ypTNM was small, limiting comparison to its pTNM counterparts, it is noteworthy that the prognosis for patients categorized as stage III ypTNM was equivalent to that of patients with stage III pTNM. 33 Additionally, the ypTNM group demonstrated a high R0 resection rate (94.0”
InfluentialAraki, T., Sonoda, Y., Shimokawa, M., Otsuka, T., Hayashi, K., Honda, T., Nakao, K., Shibuki, T., Nakazawa, J., Arima, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-88005-4 · Cited by 1
Metastatic pancreatic cancer with activating BRAF V600E mutations: A case report
Li, F., & Shen, F. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i16.101665 · Cited by 1
Fremal, M., & Chedia, M. (2025) · Case Reports in Oncology · doi:10.1159/000546328 · Cited by 1
Lipid-Based Systems for Regenerative Medicine
Patel, P., Bagada, A. A., Garala, K., Singh, S. K., & Prajapati, B. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_5 · Cited by 1
Kobayashi, S., Fukushima, T., Tezuka, S., Shiraishi, K., Enomoto, M., Tsunoda, S., Hamaguchi, T., Ohishi, R., Tozuka, Y., Murakawa, M., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251351540 · Cited by 1
Nanosomal Irinotecan Targeting Pancreatic Cancer Cell Surface Neuraminidase‐1 Sialidase
Murakami, K., Yokoi, Y., Hirane, N., Otaki, M., & Nishimura, S. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501673 · Cited by 1
Nanotechnology for Soil and Water Management
Mishra, A. K., Paul, R., Grover, D., Das, R., Mishra, S., Akshu, A., Pavithra, P., Roohi, Soni, P. G., & Sharma, S. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677313-00371 · Cited by 1
Piotrowska, U., Laskowska, A. K., Kasiński, A., Kurzątkowska, M., Bocho–Janiszewska, A., Zalewska, A., Olędzka, E., & Sobczak, M. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.128410 · Cited by 1
Standards de chimiothérapie, perspectives et thérapies ciblées dans l’adénocarcinome du pancréas
Lambert, A., & Conroy, T. (2015) · ONCOLOGIE · doi:10.1007/s10269-015-2562-8 · Cited by 1
“[22] 471 6,1 vs 4,2 0,57 16 vs 1 % Asthénie : 14 %”
Martín-Richard, M., Ginés, À., Ayuso, J. R., Sabater-Orti, L., Fabregat, J., Méndez, R., Fernández‐Esparrach, G., Molero, X., Vaquero, E. C., Cuatrecasas, M., et al. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.12.008 · Cited by 1
Pancreatic cancer: moving forward, step by step
Riess, H. B. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30055-9 · Cited by 1
Emerging Technologies for the Diagnosis and Treatment of Pancreatic Cancer
Swierczewska, M., Козлов, С. В., & Adiseshaiah, P. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00022-3 · Cited by 1
Clementine, R., Mas, L., Granier, S., Colle, E., Neuzillet, C., & Hammel, P. R. (2019) · Cancer Reports and Reviews · doi:10.15761/crr.1000184 · Cited by 1
“As mentioned, the benefit of targeted therapies remains very limited [84,85].”
BackgroundVentura, M., Bernards, N., Souza, R. D., Fricke, I. B., Hendriks, B. S., Fitzgerald, J. B., Lee, H., Klinz, S. G., & Zheng, J. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01374-x · Cited by 1
Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie
Reißig, T. M., & Siveke, J. T. (2020) · Die Gastroenterologie · doi:10.1007/s11377-020-00493-0 · Cited by 1
Self-citationRosumeck, N., Timmermann, L., Klein, F., Bahra, M., Stintzig, S., Malinka, T., & Pelzer, U. (2021) · Medicina · doi:10.3390/medicina57010077 · Cited by 1
Self-citationCeniceros, L., Prados, S., & Álvarez-Gallego, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_78 · Cited by 1
Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors
Vučetić, M., Daher, B., Cassim, S., Parks, S. K., & Pouysségur, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-62026-4_2 · Cited by 1
Kraj, L., Gryziak, M., Żurawińska-Grzelka, E., & Woźniak, K. (2021) · Oncoreview · doi:10.24292/01.or.122270621 · Cited by 1
“The only prospective, randomized, phase III study unquestionably demonstrating the effectiveness of adding another chemotherapeutic agent to 5-FU/LV in the treatment of II line metastatic pancreatic cancer remains the NAPOLI-1 study [7].”
BackgroundInfluentialOstrowska-Cichocka, K., & Wojtukiewicz, M. Z. (2021) · Oncoreview · doi:10.24292/01.or.123100721 · Cited by 1
Saade-Lemus, P., Biller, L., & Bullock, A. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-87 · Cited by 1
“Over the last decade, several phase III trials have shown that combination chemotherapy regimens are associated with improved survival compared to single agent regimens in patients with advanced PDA, although often at the expense of increased toxicity (3-5).”
BackgroundContinuing Advancements in Breast Cancer Care
(2021) · ONCOLOGY · doi:10.46883/onc.2021.3501.0011 · Cited by 1
Satake, T., Morizane, C., Maruki, Y., Ohba, A., Nagashio, Y., Kondo, S., Hijioka, S., Ueno, H., & Okusaka, T. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02186-w · Cited by 1
Beumer, J. H., Kennard, B. C., Holleran, J. L., Moore, N., Zlott, J., Miller, B. M., Kummar, S., Chen, A. P., Doroshow, J. H., Park, W., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04509-8 · Cited by 1
“The camptothecin derivatives irinotecan and topotecan have demonstrated antitumor activity in various tumor types, with approvals in ovarian, colorectal, and small cell lung cancer [1], and pancreatic cancer [2].”
BackgroundManagement of malignant hypercalcemia in cancer patients—a short review
Petrasch, C., Marics, P., & Spanberger, T. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00919-9 · Cited by 1
Nanoliposomal irinotecan in metastatic pancreatic cancer – Authors' reply
Chen, L., Wang‐Gillam, A., Hoff, D. D. V., Bayever, E., & Belanger, B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30365-8 · Cited by 1
Self-citationPalliative Chemotherapy for Advanced Pancreatic Cancer
Faluyi, O. O., Chatterjee, M., & Palmer, D. H. (2018) · doi:10.1002/9781119188421.ch116 · Cited by 1
Self-citationVivaldi, C., Fornaro, L., Caparello, C., Falcone, A., & Vasile, E. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.69 · Cited by 1
Chemotherapy for Advanced Pancreatic Cancer
Sclafani, F., Cunningham, D., Okines, A. F. C., Ratnayake, G., & Chau, I. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_37-3 · Cited by 1
Self-citationDe, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch15 · Cited by 1
Preclinical Pediatric Molecular Analysis for Therapy Choice (MATCH)Preprint
Blankenship, K., Chang, T., Fan, Y., Gordon, B., Wright, W. C., Kieffer, M., Karlström, Å., Jeon, J., Patel, A. G., Dapper, J. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.22.604648 · Cited by 1
Treatment of advanced pancreatic cancer: When will the third time be a charm?
Picozzi, V. J. (2024) · Cancer · doi:10.1002/cncr.35499 · Cited by 1
Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence
Ranganathan, S., & Olivier, T. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01457 · Cited by 1
Malignome des Gastrointestinaltrakts
Folprecht, G., Geißler, M., Jehn, C. F., Lüftner, D., & Oettle, H. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-21213-0.00017-6
Nanoliposomal Irinotecan Effective for Pancreatic Cancer
Ilson, D. H. (2015) · Journal watch · doi:10.1056/nejm-jw.na39795
Nanoliposomal irinotecan in metastatic pancreatic cancer
Milosevic, I., Drysdale, H., & Goldacre, B. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30463-9
Sohal, D. P. S., Mangu, P. B., Laheru, D. A., & Khorana, A. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7463
Kleiner Fortschritt für fitte Patienten mit metastasiertem Pankreaskarzinom
Schalhorn, A. (2017) · Info Onkologie · doi:10.1007/s15004-017-5612-0
Pankreaskarzinom beim alten und geriatrischen Patienten
Härtel, N., & Rückert, F. (2018) · Springer eBooks · doi:10.1007/978-3-662-48727-3_26
Goldstein, J. B., Tang, C. Z., Hess, K. R., Hong, D. S., Subbiah, V., Jankú, F., Fu, S., Karp, D. D., Naing, A., Tsimberidou, A. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19897
New chemotherapies in gastric adenocarcinoma
Wöll, E. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0354-0
“of pancreatic cancer, nanoliposomal irinotecan is active in combination with 5FU [33].”
BackgroundCytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed
Vijayvergia, N., & Cohen, S. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-58256-6_11
Metadata
- Authors
- Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
- Affiliations
- Taipei Veterans General Hospital (TW)
- St John of God Subiaco Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Translational Genomics Research Institute (US)
- Vall d'Hebron Institute of Oncology (ES)
- Seoul National University Hospital (KR)
- Royal Marsden Hospital (GB)
- Hôpital Saint-André (FR)
- The Christie NHS Foundation Trust (GB)
- China Medical University Hospital (TW)
- Hospital de Clínicas de Porto Alegre (BR)
- TUM Klinikum (DE)
- Comprehensive Cancer Centers of Nevada (US)
- Merrimack Pharmaceuticals (United States) (US)
- Kaohsiung Medical University (TW)
- Corresponding author
- Chen, Li-Tzong
- ORCID
- Li, Chung-Pin
- Dean, Andrew
- Shan, Yan-Shen
- Jameson, Gayle
- Macarulla, Teresa
- Lee, Kyung-Hun
- Cunningham, David
- Hubner, Richard A
- Schwartsmann, Gilberto
- Siveke, Jens T
- Braiteh, Fadi
- Moyo, Victor
- Belanger, Bruce
- Chen, Li-Tzong
- Asselah, Jamil
- Barrios, Carlos Henrique
- Chang, David
- Chen, Jen-Shi
- Chen, Yeu-Chin
- Choi, Hye Jin
- Chung, Vincent
- Cubillo, Antonio
- Dragovich, Tomislav
- Fein, Luis Enrique
- Fuchs, Martin
- Korbenfeld, Ernesto
- Lee, Fa-Chyi
- Lee, Kuan-Der
- Ma, Wen Wee
- Palmer, Daniel
- Pant, Shubham
- Park, Joon Oh
- Pelzer, Uwe
- Rau, Kun-Ming
- Raoul, Jean-Luc
- Richards, Donald
- Ross, Paul
- Stahalova, Vladimira
- Sternberg, Cora
- Seufferlein, Thomas
- Tebbutt, Niall
- Wadlow, Raymond
- Wong, Mark
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 387
- Issue
- 10018
- Pages
- 545-557
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2187917981
- Cited by
- 1,222
- References
- 29
- Citations by year
- 2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- 5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
- MeSH terms
- Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
